David J Dooley

Summary

Affiliation: Pfizer Global Research and Development
Country: USA

Publications

  1. ncbi Stimulus-dependent modulation of [(3)H]norepinephrine release from rat neocortical slices by gabapentin and pregabalin
    D J Dooley
    Department of Neuroscience Therapeutics, Pfizer Global Research and Development, Ann Arbor, Michigan 48105, USA
    J Pharmacol Exp Ther 295:1086-93. 2000
  2. ncbi Preferential action of gabapentin and pregabalin at P/Q-type voltage-sensitive calcium channels: inhibition of K+-evoked [3H]-norepinephrine release from rat neocortical slices
    David J Dooley
    Department of CNS Pharmacology, Pfizer Global Research and Development, Ann Arbor, Michigan 48105, USA
    Synapse 45:171-90. 2002
  3. ncbi Ca2+ channel alpha2delta ligands: novel modulators of neurotransmission
    David J Dooley
    Department of CNS Pharmacology, Pfizer Global Research and Development, Ann Arbor, MI 48105, USA
    Trends Pharmacol Sci 28:75-82. 2007
  4. ncbi Carboxylate bioisosteres of gabapentin
    Carmen E Burgos-Lepley
    Pfizer Global Research and Development, Michigan Laboratories, 2800 Plymouth Road, Ann Arbor, MI 48105, USA
    Bioorg Med Chem Lett 16:2333-6. 2006
  5. ncbi Inhibition of neuronal Ca(2+) influx by gabapentin and pregabalin in the human neocortex
    Klaus Fink
    Department of Pharmacology and Toxicology, University of Bonn Medical School, Reuterstrasse 2b, 53113 Bonn, Germany
    Neuropharmacology 42:229-36. 2002
  6. ncbi Dual effects of gabapentin and pregabalin on glutamate release at rat entorhinal synapses in vitro
    Mark O Cunningham
    Department of Physiology, School of Medical Sciences, University Walk, University of Bristol, Bristol, BS8 1TD, UK
    Eur J Neurosci 20:1566-76. 2004
  7. ncbi Comparison of the ORL1 receptor-mediated inhibition of noradrenaline release in human and rat neocortical slices
    Axel Rominger
    , Neurozentrum, Breisacherstr. 64, D-79106 Freiburg, Germany
    Br J Pharmacol 135:800-6. 2002

Collaborators

  • David J Wustrow
  • Mark J Field
  • Jacob B Schwarz
  • Susan M Lotarski
  • Manfred Gothert
  • K Fink
  • Douglas Feltner
  • Carmen E Burgos-Lepley
  • Mark O Cunningham
  • Axel Rominger
  • Charles P Taylor
  • Justin S Bryans
  • Karen Walters
  • Clare O Kneen
  • Nirmala Suman-Chauhan
  • Lisa R Thompson
  • Thomas Capiris
  • Madhu Cherukury
  • Simon A Osborne
  • Jack J Kinsora
  • Cindy M Donovan
  • Ayman El-Kattan
  • Mark G Vartanian
  • Roland S G Jones
  • Gavin L Woodhall
  • Sarah E Thompson
  • Alexander T McKnight
  • Josef Zentner
  • Mila Vlaskovska
  • Thomas J Feuerstein
  • Rolf Jackisch

Detail Information

Publications7

  1. ncbi Stimulus-dependent modulation of [(3)H]norepinephrine release from rat neocortical slices by gabapentin and pregabalin
    D J Dooley
    Department of Neuroscience Therapeutics, Pfizer Global Research and Development, Ann Arbor, Michigan 48105, USA
    J Pharmacol Exp Ther 295:1086-93. 2000
    ..This type of modulation of neurotransmitter release may be integral to the clinical pharmacology of these drugs...
  2. ncbi Preferential action of gabapentin and pregabalin at P/Q-type voltage-sensitive calcium channels: inhibition of K+-evoked [3H]-norepinephrine release from rat neocortical slices
    David J Dooley
    Department of CNS Pharmacology, Pfizer Global Research and Development, Ann Arbor, Michigan 48105, USA
    Synapse 45:171-90. 2002
    ..These findings suggest a selective modulation of P/Q-type VSCC that are implicated in neurotransmission and several GBP-responsive pathologies...
  3. ncbi Ca2+ channel alpha2delta ligands: novel modulators of neurotransmission
    David J Dooley
    Department of CNS Pharmacology, Pfizer Global Research and Development, Ann Arbor, MI 48105, USA
    Trends Pharmacol Sci 28:75-82. 2007
    ..This modulation is characterized by a reduction of the excessive neurotransmitter release that is observed in certain neurological and psychiatric disorders...
  4. ncbi Carboxylate bioisosteres of gabapentin
    Carmen E Burgos-Lepley
    Pfizer Global Research and Development, Michigan Laboratories, 2800 Plymouth Road, Ann Arbor, MI 48105, USA
    Bioorg Med Chem Lett 16:2333-6. 2006
    ..Further characterization of alpha2-delta binding compounds 14a and 14b revealed a similar pattern of functional in vitro and in vivo activity to gabapentin 1...
  5. ncbi Inhibition of neuronal Ca(2+) influx by gabapentin and pregabalin in the human neocortex
    Klaus Fink
    Department of Pharmacology and Toxicology, University of Bonn Medical School, Reuterstrasse 2b, 53113 Bonn, Germany
    Neuropharmacology 42:229-36. 2002
    ....
  6. ncbi Dual effects of gabapentin and pregabalin on glutamate release at rat entorhinal synapses in vitro
    Mark O Cunningham
    Department of Physiology, School of Medical Sciences, University Walk, University of Bristol, Bristol, BS8 1TD, UK
    Eur J Neurosci 20:1566-76. 2004
    ....
  7. ncbi Comparison of the ORL1 receptor-mediated inhibition of noradrenaline release in human and rat neocortical slices
    Axel Rominger
    , Neurozentrum, Breisacherstr. 64, D-79106 Freiburg, Germany
    Br J Pharmacol 135:800-6. 2002
    ..This study provides the first evidence that N/OFQ modulates [(3)H]-NA release in human neocortex via specific ORL1 receptors most likely located on noradrenergic axon terminals...